Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLSTICE: VIR-2218 and VIR-3434 in chronic hepatitis D
2024-512203-40-00Phase 2Authorised
- Sponsor
- Vir Biotechnology
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 9
01
Overview
Phase 2 trial of elebsiran and tobevibart in hepatitis D (HDV) and Chronic Hepatitis B (CHB), sponsored by Vir Biotechnology. Primary endpoints: Combined virologic and biochemical response at Week 24 and Safety. Planned start Nov 2022; status: authorised.
02
Drugs
elebsirantobevibart
03
Conditions
hepatitis D (HDV)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2024-512203-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512203-40-00.